Editas Medicine Inc
Research Editas Medicine Inc (EDIT) on Bullrun: market cap USD 503.58M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEDIT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 503.58M
- Financial periodQ2 2026
- RevenueUSD 11.89M
- Net income-USD 18.23M
- Free cash flow-USD 29.67M
Valuation Snapshot
latest market cap is USD 503.58M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 40.52M | -USD 160.06M | -USD 165.85M | n/a | -1.8 | USD 146.65M | USD 58.61M | USD 27.29M |
| FY2024 | USD 32.31M | -USD 237.09M | -USD 219.11M | n/a | -2.88 | USD 131.54M | USD 57.43M | USD 134.27M |
| FY2023 | USD 78.12M | -USD 153.22M | -USD 136.90M | n/a | -2.02 | USD 123.65M | USD 0 | USD 349.10M |
| FY2022 | USD 19.71M | -USD 220.43M | -USD 181.47M | n/a | -3.21 | USD 141.52M | USD 43.95M | USD 360.68M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 503.58M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 200.63M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 105.07M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 827.35M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 609.93M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.82B | n/a | n/a | n/a |
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Editas Medicine Inc's market cap?
Editas Medicine Inc's market capitalization is USD 503.58M.
What does Editas Medicine Inc do?
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues.